C5-substituted quinazolines [37], the most clinically advanced therapeutic candidates emerged from these screens, potently inhibit the activity of the scavenger decapping enzyme DcpS [41] and improve survival and motor phenotype in SMA mice [42]–[44]. The gene discussed is DCPS; the disease is proximal spinal muscular atrophy.